Nykredit Realkredit A/S
To Nasdaq Copenhagen
25 January 2021
Nykredit Realkredit A/S – New final terms for SEK Medium Term Note Programme
Nykredit Realkredit A/S publishes final terms for an issue of SEK 550,000,000 Floating Rate Senior Non-Preferred Notes due 2023, which are issued pursuant to Nykredit Realkredit A/S's and Nykredit Bank A/S’s €10,000,000,000 Euro Medium Term Note Programme dated 13 May 2020.
The final terms dated 25 January 2021 and the EMTN Programme dated 13 May 2020 are available for download on Nykredit's website at nykredit.com/ir.
Enquiries may be addressed to Nykredit Realkredit A/S, Nicolaj Legind Jensen, Executive Vice President, Funding & Capital, tel +45 44 55 11 10, or Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S3.11.2025 15:05:00 CET | Press release
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Infoblox Inc.3.11.2025 15:00:00 CET | Press release
Infoblox Surpasses 200 Customers in Breakout Year for Universal DDI™ and Announces New Capabilities for Network Transformation
Evaxion3.11.2025 15:00:00 CET | Press release
Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
F. Hoffmann-La Roche Ltd3.11.2025 15:00:00 CET | Press release
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
AIM ImmunoTech Inc.3.11.2025 14:55:00 CET | Press release
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
